Sarepta Therapeutics Inc (SRPT) - Total Assets
Based on the latest financial reports, Sarepta Therapeutics Inc (SRPT) holds total assets worth $3.18 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore SRPT cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Sarepta Therapeutics Inc - Total Assets Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Sarepta Therapeutics Inc (SRPT) net assets for net asset value and shareholders' equity analysis.
Sarepta Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Sarepta Therapeutics Inc's total assets of $3.18 Billion consist of 75.8% current assets and 24.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 23.9% |
| Accounts Receivable | $398.23 Million | 11.9% |
| Inventory | $914.74 Million | 27.3% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $28.95 Million | 0.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2025)
This chart illustrates how Sarepta Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see SRPT company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sarepta Therapeutics Inc's current assets represent 75.8% of total assets in 2025, an increase from 39.1% in 1995.
- Cash Position: Cash and equivalents constituted 23.9% of total assets in 2025, down from 30.4% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 17.0% in 1995.
- Asset Diversification: The largest asset category is inventory at 27.3% of total assets.
Sarepta Therapeutics Inc Competitors by Total Assets
Key competitors of Sarepta Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
Pharvaris BV
NASDAQ:PHVS
|
USA | $338.90 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.38 Billion |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
NANOBIOTIX S.A. SP.ADR
F:5NRA
|
Germany | €67.76 Million |
Sarepta Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.63 | 4.02 | 5.33 |
| Quick Ratio | 2.62 | 2.46 | 4.70 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.81 Billion | $1.83 Billion | $1.84 Billion |
Sarepta Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sarepta Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.53 |
| Asset Growth Rate (YoY) | -15.5% |
| Total Assets | $3.35 Billion |
| Market Capitalization | $1.77 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Sarepta Therapeutics Inc's assets below their book value (0.53x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sarepta Therapeutics Inc's assets decreased by 15.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sarepta Therapeutics Inc (1995–2025)
The table below shows the annual total assets of Sarepta Therapeutics Inc from 1995 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $3.35 Billion | -15.48% |
| 2024-12-31 | $3.96 Billion | +21.40% |
| 2023-12-31 | $3.26 Billion | +4.35% |
| 2022-12-31 | $3.13 Billion | -0.62% |
| 2021-12-31 | $3.15 Billion | +5.47% |
| 2020-12-31 | $2.98 Billion | +63.74% |
| 2019-12-31 | $1.82 Billion | +11.01% |
| 2018-12-31 | $1.64 Billion | +25.54% |
| 2017-12-31 | $1.31 Billion | +208.41% |
| 2016-12-31 | $424.10 Million | +54.91% |
| 2015-12-31 | $273.78 Million | -7.20% |
| 2014-12-31 | $295.03 Million | +1.19% |
| 2013-12-31 | $291.57 Million | +42.23% |
| 2012-12-31 | $204.99 Million | +277.05% |
| 2011-12-31 | $54.37 Million | +18.25% |
| 2010-12-31 | $45.98 Million | -23.41% |
| 2009-12-31 | $60.03 Million | +135.07% |
| 2008-12-31 | $25.54 Million | -33.91% |
| 2007-12-31 | $38.64 Million | -5.44% |
| 2006-12-31 | $40.86 Million | -27.56% |
| 2005-12-31 | $56.41 Million | +97.79% |
| 2004-12-31 | $28.52 Million | -39.51% |
| 2003-12-31 | $47.15 Million | +64.82% |
| 2002-12-31 | $28.60 Million | -15.41% |
| 2001-12-31 | $33.82 Million | -3.63% |
| 2000-12-31 | $35.09 Million | +172.00% |
| 1999-12-31 | $12.90 Million | +26.47% |
| 1998-12-31 | $10.20 Million | -45.74% |
| 1997-12-31 | $18.80 Million | +347.62% |
| 1996-12-31 | $4.20 Million | +82.61% |
| 1995-12-31 | $2.30 Million | -- |
About Sarepta Therapeutics Inc
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 ski… Read more